Mounjaro (Tirzepatide) Safety in Adolescents Ages 12 to 17

What Is the Current FDA Approval Status of Tirzepatide in Adolescents?

Tirzepatide does not hold FDA approval for any indication in patients under 18 years of age as of July 2025. Mounjaro carries approval only for type 2 diabetes in adults, and Zepbound (the same molecule, different branding) carries approval only for adult chronic weight management. Any use in a 12-to-17-year-old is off-label.

Why the Age Cutoff Exists

The FDA requires pediatric-specific safety and efficacy data before extending an indication to minors. Adolescent physiology differs from adult physiology in ways that matter for GLP-1 and GIP receptor agonists. Bone accrual peaks during early puberty, linear growth is still active, and the hypothalamic-pituitary axis is in a state of rapid change throughout this window. Drug exposure studies in adults cannot simply be extrapolated downward.

The FDA's Pediatric Research Equity Act (PREA) obligates manufacturers to conduct pediatric studies when a drug is approved for a condition that also affects children. Eli Lilly is currently running a dedicated pediatric program. Until those data are submitted and reviewed, the approval gap remains. The FDA's pediatric drug development framework can be reviewed at the FDA pediatric page.

What the Approval Gap Means Clinically

Off-label prescribing is legal and common in pediatrics. It does not mean a drug is unsafe. It means the formal benefit-risk determination for that age group has not yet been completed by regulators. Clinicians who prescribe tirzepatide to adolescents carry heightened documentation and monitoring obligations, and they should engage the family in a detailed informed-consent conversation that covers the absence of age-specific trial data.

What Does the Trial Evidence Actually Show for Teens?

No completed, published, randomized controlled trial of tirzepatide in adolescents aged 12 to 17 had reported primary outcomes as of July 2025. The evidence base for this age group comes from three sources: adult trials that set the efficacy and safety context, completed adolescent trials of related GLP-1 drugs, and preliminary data from ongoing pediatric programs.

SURPASS-2 as the Adult Benchmark

SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. The 15 mg tirzepatide arm produced a mean A1C reduction of 2.37 percentage points versus 1.86 percentage points with semaglutide, and mean body weight fell by 11.2 kg versus 5.7 kg. Nausea occurred in 17 to 22 percent of tirzepatide participants depending on dose, and vomiting in 6 to 10 percent [1]. These GI rates matter for adolescents because teenagers may be less equipped to manage persistent nausea, and caloric restriction during active growth phases carries different risks than in fully developed adults.

GLP-1 Adolescent Trial Data as a Proxy

Because no tirzepatide pediatric RCT has reported, clinicians reference adolescent trials of structurally related drugs. The SCALE TEENS trial (N=251) tested liraglutide 3 mg daily in adolescents aged 12 to 17 with obesity. At 56 weeks, BMI standard deviation score fell by 0.22 with liraglutide versus an increase of 0.22 with placebo, and 43.3 percent of liraglutide participants achieved at least 5 percent BMI reduction versus 18.7 percent on placebo [2]. Adverse events were predominantly GI. No serious growth velocity signals were identified in SCALE TEENS at the 56-week mark, but the trial was not powered to detect small effects on bone density.

The STEP TEENS trial (N=201) tested semaglutide 2.4 mg weekly in adolescents aged 12 to 17 with obesity and led to a mean BMI reduction of 16.1 percent versus a 0.6 percent increase in the placebo arm at 68 weeks [3]. Tirzepatide's dual GIP and GLP-1 mechanism produces larger effects in adults than semaglutide alone, so extrapolating STEP TEENS results directly to tirzepatide would likely underestimate both the efficacy and the intensity of adverse effects.

SURPASS-PEDS: What to Expect

Eli Lilly's SURPASS-PEDS program is evaluating tirzepatide in pediatric patients with type 2 diabetes. The trial design mirrors adult SURPASS protocols with added growth-monitoring endpoints. Completion is anticipated in 2025 to 2026. When those data publish, they will be the first direct evidence for this drug in this age group. Until then, every clinical decision about adolescent tirzepatide use rests on inference from adult data and proxy evidence from the liraglutide and semaglutide pediatric programs.

What Are the Primary Safety Concerns in Adolescents?

The safety signals known from adult trials do not map one-to-one onto adolescent risk profiles. Several concerns require separate consideration in patients aged 12 to 17.

Gastrointestinal Adverse Events

Nausea, vomiting, diarrhea, and constipation are the most common adverse events with tirzepatide across all age groups in adults. In SURPASS-2, GI events led to drug discontinuation in 4.3 percent of the 15 mg group [1]. In the STEP TEENS semaglutide trial, 9.5 percent of adolescent participants discontinued due to adverse events, and GI symptoms were the dominant reason [3]. Adolescents may experience stronger social and psychological distress from nausea at school or during peer activities, which can compound adherence problems.

Clinicians should titrate slowly. The adult protocol of 2.5 mg for four weeks before dose escalation represents a minimum ramp, and many pediatric obesity specialists prefer longer intervals at each dose level for younger patients.

Linear Growth and Bone Accrual

This is the area of greatest biological concern unique to adolescents. GLP-1 and GIP receptors are expressed in osteoblasts, and animal studies have shown changes in bone turnover markers with GLP-1 receptor agonist exposure. A 2023 review in the Journal of Bone and Mineral Research noted that GLP-1 receptor agonists may modestly increase bone formation markers while reducing bone resorption, but the net clinical effect on peak bone mass in growing adolescents remains unknown [4]. Peak bone mass is largely determined by age 18 to 20, and any interference during this window could have lifelong fracture-risk consequences.

Growth velocity monitoring (height measured every three months, plotted against WHO or CDC growth charts) is mandatory in any adolescent receiving tirzepatide off-label. A drop in height velocity percentile by more than 25 points should prompt endocrine evaluation and reconsideration of therapy.

Mental Health and Eating Disorder Screening

Adolescents with obesity carry rates of depression and anxiety roughly two to three times higher than the general pediatric population, according to data from the CDC National Survey of Children's Health [5]. GLP-1 receptor agonists suppress appetite through central mechanisms. In a subset of adults, this suppression has been associated with mood changes and, in post-marketing reports to the FDA, with suicidal ideation (though causality has not been established). The FDA added a pharmacovigilance requirement for ongoing safety monitoring of neuropsychiatric events for semaglutide and liraglutide in 2023.

Any adolescent starting tirzepatide should complete validated screening tools, the PHQ-A for depression and the SCOFF or EDE-Q for eating disorder risk, at baseline and at every follow-up visit. A history of restrictive eating, purging, or body dysmorphia is a relative contraindication. Prescribers should coordinate with a mental health provider from treatment initiation, not reactively.

Caloric Adequacy and Micronutrient Status

Tirzepatide reduces appetite substantially. In adults, protein intake during weight loss is a key determinant of lean mass preservation. In adolescents, inadequate caloric intake during a phase of rapid growth, muscle development, and neurological maturation carries greater risk. A registered dietitian with pediatric expertise should assess dietary intake before and during treatment. Specific attention to iron, vitamin D, calcium, and zinc is warranted, since these are frequently inadequate in adolescent diets even without GLP-1-induced appetite suppression [6].

How Should Tirzepatide Be Dosed and Monitored in an Adolescent?

No FDA-approved pediatric dosing schedule exists. The following framework reflects clinical reasoning from adult pharmacokinetics, pediatric GLP-1 trial protocols, and the emerging consensus among pediatric obesity specialists.

Proposed Monitoring Framework for Off-Label Adolescent Use

The table below summarizes a conservative monitoring approach. This is not a substitute for individualized clinical judgment or specialist consultation.

| Timepoint | Assessment | |---|---| | Baseline | Height, weight, BMI, A1C, fasting glucose, lipids, LFTs, renal function, thyroid (TSH), PHQ-A, eating disorder screen, pregnancy test if applicable | | Week 4 | Weight, GI symptom diary review, mood check-in, dose escalation decision | | Month 3 | Height velocity measurement, BMI, metabolic panel, PHQ-A, dietary review | | Month 6 | Full baseline labs repeated, bone health assessment (vitamin D, calcium), growth chart updated | | Month 12 | DXA scan consideration if growth velocity concerns, full metabolic panel, continued psychological review | | Ongoing every 3 months | Height, weight, BMI, blood pressure, PHQ-A, dietary adequacy |

Dose Escalation Considerations

Adult starting dose is 2.5 mg weekly for four weeks, then escalation by 2.5 mg increments every four weeks as tolerated. Pediatric obesity specialists using GLP-1 drugs off-label in adolescents often extend each dose level to six to eight weeks, particularly in patients with a strong nausea response. Maximum dose in adults is 15 mg weekly. Whether that ceiling should be lower in adolescents is not yet established by trial data.

Body weight-based dosing has not been validated for tirzepatide in this age group. For context, the liraglutide pediatric approval uses a flat 3 mg maximum daily dose regardless of weight, after a slow titration, because weight-based dosing did not improve outcomes in SCALE TEENS [2].

When to Pause or Discontinue

Tirzepatide should be paused or discontinued in an adolescent if any of the following occur: acute pancreatitis, gallbladder disease requiring intervention, clinically significant growth deceleration, worsening depression or emergence of suicidal ideation, restrictive eating patterns consistent with anorexia nervosa, persistent GI adverse events preventing adequate caloric intake, or pregnancy. Medullary thyroid carcinoma history or MEN2 syndrome remains an absolute contraindication regardless of age, consistent with the FDA label [7].

Which Adolescents Might Be Considered for Off-Label Tirzepatide?

Because no FDA approval exists, off-label use should be reserved for adolescents in whom other approaches have failed and where the metabolic burden of untreated disease is significant.

Type 2 Diabetes With Inadequate Glycemic Control

Type 2 diabetes in adolescents is more aggressive than the adult form. The TODAY study (N=699) showed that 52 percent of adolescents with type 2 diabetes experienced treatment failure on metformin alone within four years, and that failure was faster in younger patients and those with higher baseline A1C [8]. For an adolescent with type 2 diabetes who has not reached glycemic targets on metformin and lifestyle modification, a GLP-1 or GIP/GLP-1 receptor agonist is a clinically defensible choice even off-label, provided informed consent is thorough and monitoring is intensive.

Liraglutide 1.8 mg daily does hold FDA approval for type 2 diabetes in pediatric patients aged 10 and older. That approval makes liraglutide the first-line GLP-1 option in pediatric T2D. Tirzepatide would represent a second step when liraglutide fails or is not tolerated.

Severe Obesity Without Diabetes

For adolescents with obesity (BMI at or above the 95th percentile for age and sex) without diabetes, the calculus is more conservative. Semaglutide 2.4 mg weekly has FDA approval for chronic weight management in adolescents aged 12 and older under the brand name Wegovy, granted in December 2022 [9]. Tirzepatide does not. A prescriber choosing tirzepatide over semaglutide for an adolescent with obesity but without T2D would need to justify that choice carefully, given the availability of an FDA-approved alternative in the same drug class.

What Do Guidelines Say About GLP-1 Drugs in Adolescents?

The American Academy of Pediatrics (AAP) published its first comprehensive clinical practice guideline on pediatric obesity in January 2023. The guideline recommends offering weight-loss pharmacotherapy for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile) when lifestyle interventions alone are insufficient [10]. The AAP guideline specifically endorses orlistat, phentermine-topiramate, and GLP-1 receptor agonists as pharmacotherapy options, but notes that drug selection should be guided by approved indications and available evidence.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "We recommend using pharmacotherapy only as an adjunct to lifestyle modification and behavioral interventions, not as a replacement for them, in pediatric patients with obesity." [11] This reflects a consensus that medication is one component of a broader treatment program, not a standalone fix.

The American Diabetes Association (ADA) Standards of Care in Diabetes 2024 recommends that adolescents with type 2 diabetes who do not achieve glycemic targets with metformin and lifestyle modification should be considered for additional pharmacotherapy, and specifically lists GLP-1 receptor agonists with approved pediatric indications as the preferred add-on agents [12].

None of these guidelines endorse tirzepatide specifically for adolescents, because the pediatric data do not yet exist.

How Does Tirzepatide Compare to Other Options for Adolescents?

For adolescents with obesity or type 2 diabetes, several agents have stronger regulatory footing than tirzepatide.

Semaglutide vs. Tirzepatide in Adults

In adults, tirzepatide at 15 mg produces greater mean weight loss than semaglutide 2.4 mg. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced a mean body weight reduction of 22.5 percent at 72 weeks versus placebo [13]. Semaglutide 2.4 mg produced 14.9 percent mean weight loss at 68 weeks in STEP-1 (N=1,961) [14]. The gap in efficacy is real. Whether this gap translates to adolescents is unknown, but it is one reason clinicians may consider tirzepatide for adolescents who have failed semaglutide.

Liraglutide vs. Semaglutide vs. Tirzepatide in the Pediatric Context

Liraglutide holds the most complete pediatric regulatory record: FDA approval for type 2 diabetes in patients aged 10 and older, and for obesity in adolescents aged 12 and older (Saxenda). Semaglutide holds approval for obesity in adolescents aged 12 and older (Wegovy). Tirzepatide holds neither. This creates a clear hierarchy: liraglutide or semaglutide first, tirzepatide only when those options have been tried and found inadequate.

Practical Steps for Families and Clinicians

If a family is asking about Mounjaro for an adolescent, the conversation should cover five concrete points.

First, confirm that FDA-approved options (semaglutide for obesity, liraglutide for T2D or obesity) have been considered or tried. Second, secure referral to a pediatric endocrinologist or adolescent medicine specialist with obesity expertise before initiating any GLP-1 therapy. Third, enroll the adolescent in a multidisciplinary program that includes dietary counseling, physical activity support, and behavioral health. Fourth, document informed consent explicitly noting that tirzepatide is not approved for this age group and that long-term pediatric safety data are not yet available. Fifth, establish a monitoring schedule that includes growth velocity, mental health screening, and metabolic labs at minimum every three months.

The AAP clinical practice guideline on obesity (2023) is freely accessible to families and clinicians at PubMed and serves as a useful orientation document for this conversation [10].